Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo.

Patients with vitiligo often have antibodies to pigment cells. To examine whether there is a relation between the presence of such antibodies and disease activity, sera of 24 patients with vitiligo (10 with active and 14 with inactive disease) and 19 normal individuals were tested for antibodies to pigment cell surface antigens using a live cell enzyme-linked immunoabsorbent assay. IgG pigment cell antibodies were present in 80% (eight of 10) of patients with active vitiligo but in none of those with inactive disease or in normal individuals. The antibody level of patients with active vitiligo (mean binding index [BI] 3.3 +/- 0.59) was significantly higher than in patients with inactive disease (BI 0.96 +/- 0.04) or normal individuals (BI 1.0 +/- 0.04, p less than 0.001). Antibodies present in eight patients with high titers of pigment cell antibodies reacted to three of four pigment cells but to only one of six unrelated cells. These findings indicate that a correlation exists between the incidence and level of pigment cell antibodies and the activity of vitiligo, and support the hypothesis that vitiligo is an autoimmune disease mediated by an immune reaction to pigment cells.

[1]  J. Bystryn,et al.  Enhanced Susceptibility of Melanocytes to Different Immunologic Effector Mechanisms In Vitro: Potential Mechanisms for Postinflammatory Hypopigmentation and Vitiligo , 1988 .

[2]  D. Emerson,et al.  Western blot analysis of serum antibody reactivity with human melanoma cell antigens in alopecia areata and vitiligo. , 1988, Clinical immunology and immunopathology.

[3]  J. Bystryn,et al.  Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. , 1988, The Journal of investigative dermatology.

[4]  R. Saxton,et al.  Gangliosides of human melanoma , 1989, Cancer.

[5]  R. Saxton,et al.  Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells , 1987, International journal of cancer.

[6]  G. Naughton,et al.  Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. , 1986, Journal of the American Academy of Dermatology.

[7]  G. Naughton,et al.  Antibodies to Surface Antigens of Pigmented Cells in Animals with Vitiligo 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  G. Naughton,et al.  THE SIGNIFICANCE OF VITILIGO ANTIBODIES , 1985, The Journal of dermatology.

[9]  D. Doniach,et al.  ANTIBODIES TO MELANOCYTES IN VITIUGO , 1984, The Lancet.

[10]  G. Naughton,et al.  Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. , 1983, The Journal of investigative dermatology.

[11]  G. Naughton,et al.  Antibodies to normal human melanocytes in vitiligo , 1983, The Journal of experimental medicine.

[12]  M. Eisinger,et al.  Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Nordlund,et al.  VITILIGO: THE LOSS OF PIGMENT IN SKIN, HAIR AND EYES , 1978, The Journal of dermatology.

[14]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.